Kedudukan dalam Saham
#12747
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Harga Saham
$22.26
Disegerakkan terakhir: 2024-03-22
Perubahan (1 tahun)
0.00%
Perdagangan Graphite Bio, Inc. (GRPH)
Harga GRPH dengan permodalan pasaran b
Modal pasaran bagi Graphite Bio, Inc.(GRPH)
Modal Pasaran: $553.40M
Sehingga August 2026, Graphite Bio, Inc. mempunyai modal pasaran sebanyak $553.40M. Ini menjadikan Graphite Bio, Inc. syarikat ke-12747th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Graphite Bio, Inc. dari 2021 hingga 2026
GRPH berbanding dengan 5 teratas yang paling popular stocks
| Harga GRPH |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.264T
|
+951,087.60%
|
|
|
|
|
$4.701T
|
+849,426.54%
|
|
|
|
|
$4.177T
|
+754,721.34%
|
|
|
|
|
$3.817T
|
+689,709.24%
|
|
|
|
|
$2.866T
|
+517,850.72%
|
